hydroxychloroquine has been researched along with Adverse Drug Event in 61 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We describe using the electronic PharmaCheck system to screen high-risk situations of adverse drug events (ADEs), particularly targeting prescriptions of lopinavir/ritonavir (LPVr) and hydroxychloroquine (HCQ) in the presence of contraindications or prescriptions outside institutional guidelines." | 8.31 | Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. ( Bonnabry, P; Eggimann, F; Grauser, D; Grosgurin, O; Guignard, B; Reny, JL; Samer, C; Skalafouris, C; Stirnemann, J, 2023) |
| "Combination treatments for patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX) alone include the addition of a tumor necrosis factor inhibitor (TNFi) or the addition of sulfasalazine (SSZ) and hydroxychloroquine to MTX (triple therapy)." | 7.91 | Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. ( Cannon, GW; Curtis, JR; Erhardt, DP; Mikuls, TR; Sauer, BC; Teng, CC, 2019) |
| "Brucellosis is associated with a high recurrence rate and requires more than one course of standard treatment; therefore, more research is required to find more effective treatments that lead to prompt recovery, and reduce the relapse of disease." | 6.87 | Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial. ( Ghasemi Basir, HR; Hashemi, SH; Keramat, F; Majzoobi, MM; Mamani, M; Poorolajal, J, 2018) |
| "To report a rare case of cystoid macular edema (CME) as a presentation of acute hydroxychloroquine-related retinal toxicity." | 4.31 | Unusual Presentation of Acute Hydroxychloroquine Retinopathy. ( Cheng, CK; Lian, YY; Ma, YC, 2023) |
| " We describe using the electronic PharmaCheck system to screen high-risk situations of adverse drug events (ADEs), particularly targeting prescriptions of lopinavir/ritonavir (LPVr) and hydroxychloroquine (HCQ) in the presence of contraindications or prescriptions outside institutional guidelines." | 4.31 | Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19. ( Bonnabry, P; Eggimann, F; Grauser, D; Grosgurin, O; Guignard, B; Reny, JL; Samer, C; Skalafouris, C; Stirnemann, J, 2023) |
| "Combination treatments for patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX) alone include the addition of a tumor necrosis factor inhibitor (TNFi) or the addition of sulfasalazine (SSZ) and hydroxychloroquine to MTX (triple therapy)." | 3.91 | Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. ( Cannon, GW; Curtis, JR; Erhardt, DP; Mikuls, TR; Sauer, BC; Teng, CC, 2019) |
| "To perform a systematic review on the psychiatric adverse effects of chloroquine (CQ) and hydroxychloroquine (HCQ); to summarize what is known about psychiatric adverse effects of these drugs; to compare clinical trials, populational studies, and case report studies; and to increase awareness of the potential psychiatric adverse effects of these drugs." | 3.01 | Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies. ( Cao, B; Chakravarty, S; Greenshaw, AJ; Liu, YS; Passos, IC; Talarico, F, 2023) |
| "Brucellosis is associated with a high recurrence rate and requires more than one course of standard treatment; therefore, more research is required to find more effective treatments that lead to prompt recovery, and reduce the relapse of disease." | 2.87 | Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial. ( Ghasemi Basir, HR; Hashemi, SH; Keramat, F; Majzoobi, MM; Mamani, M; Poorolajal, J, 2018) |
| " In addition to the ongoing research and development of vaccines, there is still a dire need for safe and effective drugs for the control and treatment against the SARS-CoV-2 virus infection." | 2.82 | Safety profile of COVID-19 drugs in a real clinical setting. ( Bhardwaj, M; Chiu, MN; Sah, SP, 2022) |
| " Typically, the doses were 2 to 5 times greater than the AAO recommendation (adjusted to weight) to avoid toxic retinopathy, the most undesirable ocular side effect." | 2.72 | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. ( Altemir-Gómez, I; Fambuena-Muedra, I; Hershko, S; Jiménez-García, M; Tobarra-López, A, 2021) |
| " While the mechanisms for the differential responses to drug therapy are unclear, variation in drug exposure with the same dosing protocol related to pharmacogenetic and pharmacokinetic factors may contribute." | 2.55 | Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. ( Mok, CC, 2017) |
| " A disproportionality analysis was performed to determine adverse effects reported in non-Covid and Covid patients." | 1.91 | Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions. ( Fernandez-Araque, AM; Martín Arias, LH; Merino Kolly, N; Sainz-Gil, M; Sanz Fadrique, R; Velasco-González, V; Verde Rello, Z, 2023) |
| " Any adverse events that required dose reduction or cessation of hydroxychloroquine, indicating intolerance to the drug, were recorded for up to 26 weeks after initiation of hydroxychloroquine." | 1.91 | Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus. ( Araki, K; Hirata, S; Ishitoku, M; Kohno, H; Masuda, S; Mokuda, S; Oka, N; Sugimoto, T; Watanabe, H; Yorishima, A; Yoshida, Y, 2023) |
| "Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)." | 1.72 | Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions. ( Cao, X; Gao, B; Pan, M; Shuai, Z; Tan, T; Wang, J; Xia, Q; Yang, C, 2022) |
| "Hydroxychloroquine (HCQ) has been extensively used during the COVID-19 pandemic both as a therapeutic and prophylactic drug." | 1.72 | Hydroxychloroquine: Adverse Drug Reaction Profile of an Old Drug in a New Situation. ( Bhandari, B; Chopra, D; Rai, J; Sidhu, JK; Srivastava, S; Upadhyay, R, 2022) |
| "Hydroxychloroquine was among the first receiving attention." | 1.72 | Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data. ( Bonaldo, G; Montanaro, N; Motola, D, 2022) |
| "In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients." | 1.62 | Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. ( Badowski, ME; Beardsley, JR; Borkowski, JL; Dairem, A; Fong, K; Hale, CM; Michienzi, SM; Moore, WJ; Pallotta, AM; Polisetty, RS; Postelnick, MJ; Rhodes, NJ; Schulz, LT; Shah, A; Spivak, ES; Srinivas, P, 2021) |
| " The goal of this study was to predict the potential of 25 small molecule drugs in clinical trials for COVID-19 to cause clinically relevant drug-drug interactions (DDIs), which could lead to potential adverse drug reactions (ADRs) with the use of concomitant medications." | 1.62 | Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. ( Enogieru, OJ; Giacomini, KM; Jakobsen, S; Koleske, ML; Kosti, I; Oskotsky, T; Rödin, M; Sirota, M; Vora, B; Yee, SW; Zou, L, 2021) |
| " Our primary outcomes were the continuation rate of HCQ treatment for 1 year and adverse events (AEs) during the treatment." | 1.56 | Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital. ( Hosokawa, Y; Oiwa, H, 2020) |
| "All cases arose because of failure by physicians to avoid dosing above published safe levels." | 1.31 | Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. ( Browning, DJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.64) | 18.7374 |
| 1990's | 1 (1.64) | 18.2507 |
| 2000's | 1 (1.64) | 29.6817 |
| 2010's | 14 (22.95) | 24.3611 |
| 2020's | 44 (72.13) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Zavala-Flores, E | 1 |
| Salcedo-Matienzo, J | 1 |
| Quiroz-Alva, A | 1 |
| Berrocal-Kasay, A | 1 |
| Dabit, JY | 1 |
| Hocaoglu, M | 1 |
| Moder, KG | 1 |
| Barkmeier, AJ | 1 |
| Smith, WM | 1 |
| O'Byrne, TJ | 1 |
| Crowson, CS | 1 |
| Duarte-García, A | 1 |
| Fallani, E | 1 |
| Cevenini, F | 1 |
| Lazzerini, PE | 1 |
| Verdini, A | 1 |
| Saponara, S | 1 |
| Ferron, PJ | 1 |
| Le Daré, B | 1 |
| Bronsard, J | 1 |
| Steichen, C | 1 |
| Babina, E | 1 |
| Pelletier, R | 1 |
| Hauet, T | 1 |
| Morel, I | 1 |
| Tarte, K | 1 |
| Reizine, F | 1 |
| Clément, B | 1 |
| Fromenty, B | 1 |
| Gicquel, T | 1 |
| Chiu, MN | 1 |
| Bhardwaj, M | 1 |
| Sah, SP | 1 |
| Gao, B | 1 |
| Tan, T | 1 |
| Cao, X | 1 |
| Pan, M | 1 |
| Yang, C | 1 |
| Wang, J | 1 |
| Shuai, Z | 1 |
| Xia, Q | 1 |
| Chopra, D | 1 |
| Bhandari, B | 1 |
| Rai, J | 1 |
| Upadhyay, R | 1 |
| Sidhu, JK | 1 |
| Srivastava, S | 1 |
| Motola, D | 1 |
| Bonaldo, G | 1 |
| Montanaro, N | 1 |
| Sainz-Gil, M | 1 |
| Merino Kolly, N | 1 |
| Velasco-González, V | 1 |
| Verde Rello, Z | 1 |
| Fernandez-Araque, AM | 1 |
| Sanz Fadrique, R | 1 |
| Martín Arias, LH | 1 |
| Sabatier, P | 1 |
| Wack, M | 1 |
| Pouchot, J | 1 |
| Danchin, N | 1 |
| Jannot, AS | 1 |
| Lian, YY | 1 |
| Ma, YC | 1 |
| Cheng, CK | 1 |
| Araújo, O | 1 |
| Hernández-Rodríguez, J | 1 |
| Pelegrín, L | 1 |
| Feliu, M | 1 |
| Boland, M | 1 |
| Hernández-Negrín, H | 1 |
| Adán, A | 1 |
| Espinosa, G | 1 |
| Cervera, R | 1 |
| Hentschke-Lopes, M | 1 |
| Botton, MR | 1 |
| Borges, P | 1 |
| Freitas, M | 1 |
| Mancuso, ACB | 1 |
| Matte, U | 1 |
| Oguntuyo, K | 1 |
| Schuftan, D | 1 |
| Guo, J | 1 |
| Simmons, D | 1 |
| Bhagavan, D | 1 |
| Moreno, JD | 1 |
| Kang, PW | 1 |
| Miller, E | 1 |
| Silva, JR | 1 |
| Huebsch, N | 1 |
| Talarico, F | 1 |
| Chakravarty, S | 1 |
| Liu, YS | 1 |
| Greenshaw, AJ | 1 |
| Passos, IC | 1 |
| Cao, B | 1 |
| Yoshida, Y | 3 |
| Oka, N | 3 |
| Yorishima, A | 3 |
| Masuda, S | 3 |
| Ishitoku, M | 3 |
| Araki, K | 3 |
| Kohno, H | 3 |
| Watanabe, H | 3 |
| Sugimoto, T | 3 |
| Mokuda, S | 3 |
| Hirata, S | 3 |
| Kellner, U | 3 |
| Kellner, S | 3 |
| Weinitz, S | 3 |
| Farmand, G | 3 |
| Pesqué, D | 3 |
| Pérez-Manich, J | 3 |
| García-Díez, I | 3 |
| Segura, S | 3 |
| Ferran, M | 3 |
| Gonzàlez-Farré, M | 3 |
| Pujol, RM | 3 |
| Giménez-Arnau, AM | 3 |
| Ezemma, O | 1 |
| Devjani, S | 1 |
| Jothishankar, B | 1 |
| Kelley, KJ | 1 |
| Senna, MM | 1 |
| Aït Moussa, L | 1 |
| Tebaa, A | 1 |
| Alj, L | 1 |
| Sefiani, H | 1 |
| Meski, FZ | 1 |
| Khattabi, A | 1 |
| Soulaymani Bencheikh, R | 1 |
| Mehnert, JM | 1 |
| Kaveney, AD | 1 |
| Malhotra, J | 1 |
| Spencer, K | 1 |
| Portal, D | 1 |
| Goodin, S | 1 |
| Tan, AR | 1 |
| Aisner, J | 1 |
| Moss, RA | 1 |
| Lin, H | 1 |
| Bertino, JR | 1 |
| Gibbon, D | 1 |
| Doyle, LA | 1 |
| White, EP | 1 |
| Stein, MN | 1 |
| Xie, WH | 1 |
| Zhang, ZL | 1 |
| Dahrouj, M | 1 |
| Young, L | 1 |
| Dias-Santos, A | 1 |
| Tavares Ferreira, J | 1 |
| Pinheiro, S | 1 |
| Cunha, JP | 1 |
| Alves, M | 1 |
| Papoila, AL | 1 |
| Moraes-Fontes, MF | 1 |
| Proença, R | 1 |
| Sharma, AN | 1 |
| Mesinkovska, NA | 1 |
| Paravar, T | 1 |
| Lipner, SR | 1 |
| Scher, RK | 1 |
| Chai, PR | 1 |
| Ferro, EG | 1 |
| Kirshenbaum, JM | 1 |
| Hayes, BD | 1 |
| Culbreth, SE | 1 |
| Boyer, EW | 1 |
| Erickson, TB | 1 |
| Brest, P | 1 |
| Benzaquen, J | 1 |
| Klionsky, DJ | 2 |
| Hofman, P | 1 |
| Mograbi, B | 1 |
| Paliani, U | 1 |
| Cardona, A | 1 |
| Hosokawa, Y | 1 |
| Oiwa, H | 1 |
| Tang, D | 1 |
| Li, J | 1 |
| Zhang, R | 1 |
| Kang, R | 1 |
| Capucci, A | 1 |
| Santarelli, A | 1 |
| Bartolomei, M | 1 |
| Paolizzi, C | 1 |
| Biagetti, C | 1 |
| Dappozzo, A | 1 |
| Piovaccari, G | 1 |
| Bubb, MR | 1 |
| Khurana, A | 1 |
| Katare, A | 1 |
| Agarwal, A | 1 |
| Kathirvel, P | 1 |
| Ahuja, A | 1 |
| Fernandez-Ruiz, R | 1 |
| Bornkamp, N | 1 |
| Kim, MY | 1 |
| Askanase, A | 1 |
| Zezon, A | 1 |
| Tseng, CE | 1 |
| Belmont, HM | 1 |
| Saxena, A | 1 |
| Salmon, JE | 1 |
| Lockshin, M | 1 |
| Buyon, JP | 1 |
| Izmirly, PM | 1 |
| Yokogawa, N | 1 |
| Ohno-Tanaka, A | 1 |
| Hashiguchi, M | 1 |
| Shimizu, M | 1 |
| Ozawa, H | 1 |
| Ueno, S | 1 |
| Shinoda, K | 1 |
| Browning, DJ | 3 |
| Zekarias, A | 1 |
| Watson, S | 1 |
| Vidlin, SH | 1 |
| Grundmark, B | 1 |
| Lenfant, T | 1 |
| Leroux, G | 1 |
| Costedoat-Chalumeau, N | 1 |
| Falcão, F | 1 |
| Viegas, E | 1 |
| Carmo, I | 1 |
| Soares, J | 1 |
| Falcao, M | 1 |
| Solano, M | 1 |
| Cavaco, P | 1 |
| Mendes, D | 1 |
| Rijo, J | 1 |
| Povoa, P | 1 |
| Pais Martins, A | 1 |
| Carmo, E | 1 |
| Mansinho, K | 1 |
| Fonseca, C | 1 |
| Campos, L | 1 |
| Carvalho, A | 1 |
| Mirco, A | 1 |
| Farinha, H | 1 |
| Aldir, I | 1 |
| Correia, J | 1 |
| Perez, J | 1 |
| Roustit, M | 1 |
| Lepelley, M | 1 |
| Revol, B | 1 |
| Cracowski, JL | 1 |
| Khouri, C | 1 |
| Rhodes, NJ | 1 |
| Dairem, A | 1 |
| Moore, WJ | 1 |
| Shah, A | 1 |
| Postelnick, MJ | 1 |
| Badowski, ME | 1 |
| Michienzi, SM | 1 |
| Borkowski, JL | 1 |
| Polisetty, RS | 1 |
| Fong, K | 1 |
| Spivak, ES | 1 |
| Beardsley, JR | 1 |
| Hale, CM | 1 |
| Pallotta, AM | 1 |
| Srinivas, P | 1 |
| Schulz, LT | 1 |
| Sonido, MT | 1 |
| Rallah-Baker, K | 1 |
| Gupta, M | 1 |
| Yee, SW | 1 |
| Vora, B | 1 |
| Oskotsky, T | 1 |
| Zou, L | 1 |
| Jakobsen, S | 1 |
| Enogieru, OJ | 1 |
| Koleske, ML | 1 |
| Kosti, I | 1 |
| Rödin, M | 1 |
| Sirota, M | 1 |
| Giacomini, KM | 1 |
| Fambuena-Muedra, I | 1 |
| Jiménez-García, M | 1 |
| Hershko, S | 1 |
| Altemir-Gómez, I | 1 |
| Tobarra-López, A | 1 |
| Skalafouris, C | 1 |
| Samer, C | 1 |
| Stirnemann, J | 1 |
| Grosgurin, O | 1 |
| Eggimann, F | 1 |
| Grauser, D | 1 |
| Reny, JL | 1 |
| Bonnabry, P | 1 |
| Guignard, B | 1 |
| Majzoobi, MM | 1 |
| Hashemi, SH | 1 |
| Mamani, M | 1 |
| Keramat, F | 1 |
| Poorolajal, J | 1 |
| Ghasemi Basir, HR | 1 |
| Chasset, F | 1 |
| Arnaud, L | 1 |
| Jachiet, M | 1 |
| Monfort, JB | 1 |
| Bouaziz, JD | 1 |
| Cordoliani, F | 1 |
| Bagot, M | 1 |
| Barbaud, A | 1 |
| Francès, C | 1 |
| Feng, SW | 1 |
| Luo, ZY | 1 |
| He, XQ | 1 |
| Liu, JH | 1 |
| Luo, DQ | 1 |
| Barailler, H | 1 |
| Milpied, B | 1 |
| Chauvel, A | 1 |
| Claraz, P | 1 |
| Taïeb, A | 1 |
| Seneschal, J | 1 |
| Darrigade, AS | 1 |
| Dammacco, R | 1 |
| Procaccio, P | 1 |
| Racanelli, V | 1 |
| Vacca, A | 1 |
| Dammacco, F | 1 |
| Erhardt, DP | 1 |
| Cannon, GW | 1 |
| Teng, CC | 1 |
| Mikuls, TR | 1 |
| Curtis, JR | 1 |
| Sauer, BC | 1 |
| McWilliams, DF | 1 |
| Kiely, PD | 1 |
| Young, A | 1 |
| Walsh, DA | 1 |
| Al-Bari, MA | 1 |
| Rosenbaum, JT | 1 |
| Mount, GR | 1 |
| Youssef, J | 1 |
| Lin, P | 1 |
| Mok, CC | 1 |
| Mittal, N | 1 |
| Sharma, A | 1 |
| Jose, V | 1 |
| Mittal, R | 1 |
| Wanchu, A | 1 |
| Bambery, P | 1 |
| Wang, C | 1 |
| Fortin, PR | 1 |
| Li, Y | 1 |
| Panaritis, T | 1 |
| Gans, M | 1 |
| Esdaile, JM | 1 |
| Dodson, WH | 1 |
| Holley, HL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for hydroxychloroquine and Adverse Drug Event
| Article | Year |
|---|---|
Safety profile of COVID-19 drugs in a real clinical setting.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Dexamethasone; Drug-Related Side Effects and | 2022 |
Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies.
Topics: Anxiety; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; M | 2023 |
Adverse effects of hydroxychloroquine use in patients with cicatricial alopecia: A systematic review.
Topics: Alopecia; Cicatrix; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Iat | 2023 |
Hydroxychloroquine Retinopathy in the Era of Advanced Imaging Modalities.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Drug-Related Side Effects and Adverse | 2020 |
What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects.
Topics: Antimalarials; Caregivers; Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adver | 2021 |
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.
Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-R | 2015 |
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.
Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-R | 2015 |
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.
Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-R | 2015 |
Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases.
Topics: Antimalarials; Antineoplastic Agents; Cardiovascular Agents; Chloroquine; Drug Repositioning; Drug-R | 2015 |
Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.
Topics: Animals; Calcineurin Inhibitors; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; H | 2017 |
2 trials available for hydroxychloroquine and Adverse Drug Event
| Article | Year |
|---|---|
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Dose-Response Relationship, Drug; Drug Mo | 2019 |
Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Brucellosis; Doxycycline; Drug Th | 2018 |
52 other studies available for hydroxychloroquine and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Topics: BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Drug-Related Side Effects and Adverse Reactions; Humans | 2022 |
Risk of hydroxychloroquine retinopathy in the community.
Topics: Antirheumatic Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Human | 2022 |
Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.
Topics: Azithromycin; COVID-19 Drug Treatment; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Hu | 2022 |
Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients.
Topics: Aged; Antiviral Agents; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Correlatio | 2021 |
Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.
Topics: Antirheumatic Agents; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug-Related Side Effe | 2022 |
Hydroxychloroquine: Adverse Drug Reaction Profile of an Old Drug in a New Situation.
Topics: COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine | 2022 |
Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data.
Topics: COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine | 2022 |
Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.
Topics: Chemical and Drug Induced Liver Injury; COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects | 2023 |
A data-driven pipeline to extract potential adverse drug reactions through prescription, procedures and medical diagnoses analysis: application to a cohort study of 2,010 patients taking hydroxychloroquine with an 11-year follow-up.
Topics: Antirheumatic Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Follow-Up Stu | 2022 |
Unusual Presentation of Acute Hydroxychloroquine Retinopathy.
Topics: Adult; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fluorescein An | 2023 |
Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre.
Topics: Antimalarials; Drug-Related Side Effects and Adverse Reactions; Female; Glycoproteins; Humans; Hydro | 2022 |
Sales of "COVID kit" drugs and adverse drug reactions reported by the Brazilian Health Regulatory Agency.
Topics: Azithromycin; Brazil; Coronavirus Infections; COVID-19 Drug Treatment; Drug-Related Side Effects and | 2022 |
Robust, Automated Analysis of Electrophysiology in Induced Pluripotent Stem Cell-Derived Micro-Heart Muscle for Drug Toxicity.
Topics: Antimalarials; Calcium; Drug-Related Side Effects and Adverse Reactions; Electrophysiology; Ethers; | 2022 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2023 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Drug-induced ultraviolet B photosensitivity due to hydroxychloroquine: The unexpected side effect.
Topics: Dermatitis, Allergic Contact; Dermatitis, Photoallergic; Drug-Related Side Effects and Adverse React | 2023 |
Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug-Related Side E | 2023 |
Additional Analyses to Confirm Relationship of Hydroxychloroquine Blood Levels to Retinopathy: Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; R | 2020 |
Ocular involvement in systemic lupus erythematosus patients: a paradigm shift based on the experience of a tertiary referral center.
Topics: Adult; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; | 2020 |
Response to: "Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails".
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Nails | 2020 |
Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails.
Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Nails | 2020 |
Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic.
Topics: Adult; Coronavirus Infections; COVID-19; Diazepam; Drug Overdose; Drug-Related Side Effects and Adve | 2020 |
Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
Topics: Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Chloroquine; COVID-19; COVID-19 Drug Treatmen | 2020 |
COVID-19 and hydroxychloroquine: Is the wonder drug failing?
Topics: Antimalarials; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female | 2020 |
Chloroquine in fighting COVID-19: good, bad, or both?
Topics: Autophagy; Cardiovascular Diseases; China; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 | 2020 |
Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Clinical Laboratory Tech | 2020 |
Do Hydroxychloroquine Blood Levels and Dose Identify Different Populations at Risk of Retinopathy? Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; R | 2020 |
Hydroxychloroquine-induced erythroderma: A rare adverse effect of a commonly used drug.
Topics: Dermatitis, Exfoliative; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Hy | 2020 |
Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Topics: Aged; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroqu | 2020 |
Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; R | 2021 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agent | 2020 |
Different Control Populations May Lead to Different Understanding of Hydroxychloroquine Blood Levels as a Risk Factor for Retinopathy: Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; R | 2021 |
A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
Topics: Adenosine Monophosphate; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Al | 2021 |
Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic.
Topics: Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Human | 2021 |
Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; COVID-19 Drug | 2021 |
Screening for hydroxychloroquine retinopathy in Australia.
Topics: Antirheumatic Agents; Australia; Drug-Related Side Effects and Adverse Reactions; Guidelines as Topi | 2021 |
Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data.
Topics: Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Dr | 2021 |
Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.
Topics: COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxyc | 2023 |
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Chloroquine; Drug Substitution; Drug-Related Side Eff | 2018 |
Hydroxychloroquine-Induced Reversible Hypomnesis in Systemic Lupus Erythematosus.
Topics: Adult; Antirheumatic Agents; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reaction | 2018 |
Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization.
Topics: Aged, 80 and over; Antiphospholipid Syndrome; Clinical Protocols; Desensitization, Immunologic; Drug | 2019 |
Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Eye | 2018 |
Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Drug Therapy, Combination; Drug-R | 2019 |
Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disability Evaluation; Dru | 2013 |
New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity.
Topics: Adult; Antimalarials; Biological Transport; Drug Monitoring; Drug-Related Side Effects and Adverse R | 2016 |
The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Drug-Related Side Effects and Adverse | 2016 |
Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2012 |
Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Topics: Adult; Antimalarials; Antirheumatic Agents; Cohort Studies; Drug-Related Side Effects and Adverse Re | 1999 |
Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
Topics: Aged; Antirheumatic Agents; Chloroquine; Dermatologic Agents; Drug-Related Side Effects and Adverse | 2002 |
Iatrogenic disease in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Drug-Related Side Effects and Adverse Reactions; Glucocorticoids | 1971 |